Amarin Corp Plc (AMRN)

[Chabojilo]

drc1949 YES! this is what we all feel, all understood

Vascepa (icosapent ethyl) is indicated as an adjunct to diet and exercise and in combination with a statin to reduce triglyceride TG, non-HDL-C, ApoB, LDL-C, TC, and VLDL-C in adult patients with mixed dyslipidemia and CHD or a CHD risk equivalent.

Nothing in there about Vascepa improving CVD for the indication currently under review. The references to CHD are used merely in description of the patient population being studied.

They changed the question. Many experts believe there is a RISK for Mixed Dyslipidemiacs, though there is no hard evidence... So why not allow a safe and efficacious drug that met all endpoints attempt to minimize that RISK that so many find plausible?

Niacin and Fenofibrates are used now to try to minimize risk, how bad would it be to allow Vascepa the same opportunity without having the label say it will prevent Cardio events? The goal was to reduce cardio markers and it did.